Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The year-over-year increase in revenues was driven by higher Diabetes and Obesity Care sales as GLP-1 product ... the industry’s 3.1% decline. Zacks Investment Research Image Source: Zacks ...

The company has been a big beneficiary of GLP-1 drugs that have seen soaring demand as they have been shown to greatly help with multiple health issues, including weight control. The stock has ...

Given the popularity of GLP-1 drugs and the potential for an oral GLP-1 drug launch in 2026, Lilly remains very well positioned. As such, I think the stock still looks attractive at current levels.